AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03704662 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Preoperative Fractionated Radiation Therapy and Chemotherapy
Description: Conventional concurrent chemotherapy and radiation therapy.
Study NCT00149175 — intervention group
Intervention type: OTHER
Intervention: Blood sampling, skin biopsy
Description: Blood sampling, skin biopsy in the field of the medical follow-up
Study NCT02829957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: 15mg BID for 7 days, then 20mg daily for three months
Study NCT01127477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1: Hydroxyethyl starch 130/0.4, 6 %
Description: 1: Up to 50 ml 6 % hydroxyethyl starch 130/0.4/kg body weight administered intravenously from start of surgery (skin incision) until two hours after end of surgery.
Study NCT00147537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: Phase 2 Arm A:~CP-751,871 20 mg/kg IV over 2.5 hours up to 17 cycles
Study NCT04649853 — intervention group
Intervention type: OTHER
Intervention: Standardized nursing care
Description: All patients will receive standardized evidence based nursing care
Study NCT00147537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Phase 2 Arm A:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles~Phase 2 Arm B:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles
Study NCT00147537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Phase 2 Arm A:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles~Phase 2 Arm B:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles
Study NCT00147537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: Phase 1b Dose Escalation/Expansion: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)
Study NCT00147537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Phase 1b Dose Escalation/Expansion: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles) Phase 1b Erlotinib Extension: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles)
Study NCT00147537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Phase 1b Dose Escalation/Expansion: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles) Phase 1b Erlotinib Extension: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles)
Study NCT00147537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Phase 1b Erlotinib Extension: erlotinib 150 mg/day orally every day (up to 17 cycles)
Study NCT01206270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate
Description: Testosterone undecanoate 1000mg (in 4 ml of castor oil injections) at baseline (0-week), 6-week, 18-week, 30-week
Study NCT01206270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Castor Oil
Description: 4 ml of Castor Oil injected at baseline (0-week), 6-week, 18-week, 30-week.
Study NCT03389750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Challenge Drug
Description: Intravenous administration of opioid drugs (oxycodone, oxymorphone, hydromorphone), for the purpose of comparison of their abuse potential among each other, and in comparison to placebo (saline).
Study NCT03389750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Challenge Drug
Description: Intravenous administration of opioid drugs (oxycodone, oxymorphone, hydromorphone), for the purpose of comparison of their abuse potential among each other, and in comparison to placebo (saline).
Study NCT04056637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choice of follow-up option
Description: Participant will be given the opportunity to choose from 3 follow-up options.
Study NCT04056637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-level pregnancy test
Description: The Multi-level pregnancy test (MLPT) strategy involves the use of the MLPT to estimate a pregnant person's baseline hCG range prior to beginning their abortion (i.e. prior to mifepristone administration). A follow-up test is then administered one week later to again estimate the woman's hCG range. A decline in hCG range reliably signifies absence of an ongoing pregnancy. Among clients ≤63 days' LMP at initiation of treatment, this strategy has shown to be highly effective: 100% of clients (n=1487/1487) with a decline in hCG range did not have an ongoing pregnancy and 100% of clients (n=21/21) with an ongoing pregnancy showed steady or increase in hCG range on their follow-up MLPT.
Study NCT04146909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulinemic-euglycemic clamp
Description: After an overnight fast and an equilibration period lasting 2 hours, the 2-step euglycemic-hyperinsulinemic clamp study will be performed. A primed-continuous infusion of regular insulin will be given at 8 mU/(m2 × min) during the first 2 hours, and increased to 40 mU/(m2 × min) for the subsequent 2 hours. Plasma glucose levels will be measured every 5 min, and a variable glucose infusion will be initiated to maintain levels at ∼90 mg/dl. Plasma samples will be drawn at baseline and throughout the infusion period for measurement of isotope enrichment, insulin, NEFA, glycerol turnover, and additional hormones which may be altered with lactation. Approximately 160 mL of blood will be drawn at this visit.
Study NCT01507194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Single IV dose
Study NCT04618965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
Study NCT01507194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vestipitant
Description: Single IV dose
Study NCT04618965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal dexmedetomidine
Description: Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
Study NCT01596829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Probiotic formula, 10 billion CFU in total once a day for up to 3 weeks
Study NCT04618965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine
Description: Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
Study NCT03568071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR 106
Description: The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.
Study NCT01596829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A capsule with microcrystalline cellulose matching the appearance and taste of the active comparator
Study NCT03568071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A sodium chloride infusion container with IV solution without addition of MOR106 drug product will be used as placebo in the proposed clinical study.
Study NCT00739219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apieron Insight eNO monitor
Description: The Apieron Insight(tm) eNO monitor is used to measure exhaled nitric oxide, and asthma is managed to keep eNO below an individualized target.
Study NCT03466710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposcopy
Description: Women will undergo colposcopy at 6 and 12 months after randomization. Those with CIN II will be managed according to standard of care. Those with CIN 1 6 months post randomization will have a second exam 6 months later and if still CIN I will have an exit colposcopy 6 months later.~All women in the Pap and HPV testing policies as well as all women in the colposcopy policy with CIN 1 after 2 exams will have an exit colposcopy 18 months after randomization. The exit colposcopy is a safeguard against the possibility of any false negatives in the follow up policies. The exit colposcopy will also establish the true numbers of CIN lesions in the 3 policies in order to determine their sensitivities and specificities. At the exit colposcopy,all will have an endocervical curettage,and either a minimum of 2 directed biopsies of any mucosal abnormality or in the event no abnormality is identified,2 random biopsies from the cervix.
Study NCT03466710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pap test
Description: Women will receive Pap tests at 6 and 12 months after randomization. The Pap test will be prepared using the Thinprep® system which is the standard at Calgary Laboratory Services. Women with a Pap test result of malignant, HSIL, AIS, AGC, ASC-H, or LSIL-H (>LSIL) at 6 or 12 months post randomization will be referred for colposcopic examination. Women with an ASC-US or LSIL result (\</=LSIL) will have a second follow up Pap test 6 months later (12 months post randomization). Those with a persistent result of ASC-US or LSIL or >LSIL at 6 or 12 months will be referred for colposcopic examination. Outcome in the Pap policy is positive when the histopathology is >/=CIN II. Results of \</=CIN I equal a negative outcome.~All other Pap test results will have an exit colposcopy 6 months later (18 months post randomization).
Study NCT03466710 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV test
Description: Women will have an HPV test performed on a cervical scrape sample 12 months after randomization. Women with a positive result will be referred for colposcopy. Outcome in the HPV testing policy is positive when histopathology obtained at the colposcopic exam shows CIN II. All other results equal a negative outcome. HPV negative women will have an exit colposcopy 18 months post randomization. HPV testing will be performed using Cervista™HPV HR(Third Wave Technologies Inc./Hologic Inc, Madison, WI, USA).This HPV DNA test identifies 14 high risk types (16,18,31,33,35,39,45,51,52,56,58,59,66,68). Testing will be performed on the residual cervical scrape sample which is fixed in the PreservCyt® solution of the Thinprep® liquid based system(Hologic Inc, Marlborough, Ma, USA). Cervical samples may be held for up to 24 wks at room temperature before DNA extraction.This allows time for transportation without refrigeration.The samples will be sent by overnight express delivery to the laboratory.
Study NCT04675346 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire
Study NCT03288467 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment with 5% NaOCl
Study NCT03288467 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment with 1% NaOCl
Study NCT01309425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER two 100-mg TRF
Description: 200mg TRF single oral dose
Study NCT01309425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER 50-mg TRF
Description: 50mg TRF single oral dose
Study NCT01309425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER 25-mg TRF
Description: 25mg TRF single oral dose
Study NCT01309425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER 100-mg TRF
Description: 100mg TRF single oral dose
Study NCT02867826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cap
Description: Cap-assisted endoscopy
Study NCT03240445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-203 (Period 1)
Description: ODM-203 400mg as tablets taken 30 minutes after food
Study NCT03240445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-203 (Period 2)
Description: ODM-203 400mg as tablets taken 1 hour before a light breakfast
Study NCT03240445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-203 (Periods 3-6)
Description: ODM- 203 400mg as tablets for oral administration or 400mg as oral dispersion either before/after food
Study NCT03296345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: The intervention is IV low-dose bolus ketamine as an adjuvant to standard therapy (IV opiates and NSAIDs).
Study NCT02588534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etanercept (ENBREL®) via auto-injector device
Description: single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
Study NCT02588534 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Etanercept (ENBREL®) via Manual injection
Description: single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
Study NCT04583826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAVA
Description: CAVA is a medical device containing 5 face-mounted ECG electrodes which are used to record the movement of the eyes.
Study NCT00476541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Description: Two courses of Gemtuzumab vs. no further therapy
Study NCT00728182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NA-1
Description: single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion
Study NCT00728182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion
Study NCT02236767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostar Transcranial Magnetic Stimulation Therapy System
Description: Treatment will entail daily (5 days/week) sessions of repetitive transcranial magnetic stimulation for 6 weeks employing right-sided, low frequency stimulation (1 Hz, 900 pulses/session for 30 sessions, 27,000 total pulses, intensity at 90% of the passive motor threshold) to the dorsolateral prefrontal cortex (DLPFC).
Study NCT03808909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Labor Support
Description: Participants in the intervention condition will be assigned a doula who is a lay person trained to provide emotional and practical support to individuals throughout labor and delivery.
Study NCT02298504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Description: Vital pulp therapy
Study NCT02298504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentin
Description: Vital pulp therapy
Study NCT02298504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitrebond
Description: Vital pulp therapy
Study NCT02979158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPB Low Dose
Description: Performing CPB with low dose heparin and coated equipment
Study NCT02979158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPB High Dose
Description: Performing CPB with high dose heparin and uncoated equipment
Study NCT01898091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neem Mouthrinse
Description: 10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
Study NCT01898091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Mouthrinse
Description: 10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
Study NCT01898091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mouthrinse
Description: 10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
Study NCT03864549 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Femina II
Description: 2 capsules per day until delivery
Study NCT03864549 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules per day until delivery
Study NCT01618708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synvisc-One (hylan G-F 20)
Description: 6-mL IA injection
Study NCT01618708 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 mL injection of phosphate buffered saline
Study NCT03471949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM in a population with normal OGTT
Description: The population with normal OGTT will use CGM and document their values as well as be documenting a capillary blood glucose value
Study NCT02218268 — intervention group
Intervention type: DRUG
Intervention: Pre-meal bolus
Description: Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost
Study NCT02218268 — intervention group
Intervention type: DRUG
Intervention: No meal bolus
Description: Long Acting insulin as scheduled per usual routine (given once daily)
Study NCT00356421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Human Insulin (Exubera®)
Description: Preprandial inhaled insulin regimen and administration of insulin glargine QD
Study NCT00356421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro (Humalog)
Description: Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
Study NCT03941886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin in women with high risk of preeclampsia
Description: Low-dose aspirin 150-162 mg/night or 100 mg/night if body weight \<40 Kg, from \<15 weeks till 36 weeks or, in the event of early delivery, at the onset of labor
Study NCT04291833 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group 1
Description: Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
Study NCT04291833 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group 2
Description: Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
Study NCT04291833 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group 0
Description: no protein supplementation , no Vitamin D and calcium supplementation , no exercise
Study NCT02694250 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DTRAX® Cervical Cage with DTRAX Bone Screw
Description: DTRAX Cervical Cage is an intervertebral fusion device that provides mechanical support to the spine. DTRAX Cervical Cage is intended to be used in cervical spine fusion surgery. DTRAX Bone Screw is indicated for use in arthrodesis and provides supplemental fixation. .
Study NCT03854032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03854032 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT03854032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDO1 Inhibitor BMS-986205
Description: Given PO
Study NCT03854032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo Surgery
Study NCT03854032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo Surgery
Study NCT03854032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03854032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00430859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkaline Phosphatase
Description: Intravenous over a period of 24 hours
Study NCT00430859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline over a period of 24h
Study NCT00887588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 50 mg, 100 mg and 200 mg tablets
Study NCT00887588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 40 mg, 80 mg and 160 mg tablets
Study NCT00887588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo to LCZ696 and Valsartan
Study NCT00887588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo to LCZ696 and Valsartan
Study NCT03335566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid™
Description: Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.
Study NCT03335566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SonoVue®
Description: Single Dose of SonoVue® 2.4 mL as I.V. injection.
Study NCT00663351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reflection Ceramic-Ceramic Total Hip Replacement
Description: Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.